Elsevier

Hepatology

Volume 22, Issue 6, December 1995, Pages 1863-1873
Hepatology

Special article
Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal

https://doi.org/10.1016/0270-9139(95)90216-3Get rights and content

Abstract

The aim of this study is to assess the long-term economic impact of treatment of chronic hepatitis B and C with interferon alfa. Estimates were made of the progression of the disease over a 30-year period using a transitional probability model. Cohorts of 1,000 hypothetical patients with either chronic hepatitis B or C treated with interferon alfa were compared with an untreated cohort. The costs were estimated for therapy, monitoring, and treatment of the disease, including transplantation. The cost-effectiveness of therapy was expressed in terms of cost per life saved, cost per year of life saved, and cost per quality-adjusted year of life saved. The analysis was extended to include the indirect costs to patients. The analysis included two rates of progression, two mortality rates, and discounted and undiscounted costs. Mortality in the treated group was lower, saving 18 to 31 lives in the hepatitis B virus (HBV) cohort and 13 to 22 lives in the hepatitis C virus (HCV) cohort. Fewer patients progressed to cirrhosis or decompensated cirrhosis. Discounted costs per year of life saved ranged from £2,142 to £17,128. A cost-benefit analysis indicated excess benefits over costs when values for life were included in the analysis. The potential usefulness of interferon alfa on the clinical and economic outcome of treatment is indicated from the model. These findings together with the benefits that are likely to accrue from the reduction in infectious individuals suggest that this therapy has a role to play in public health policy to contain the impact of hepatitis.

References (76)

  • D Samuel et al.

    Passive immunoprophylaxis after liver transplantation in HBsAg-posititive patients

    Lancet

    (1991)
  • A Marin

    Commodity, the bias of the world

    The Science of the Total Environment

    (1986)
  • J Broome

    Trying to value a life

    Journal of Public Economics

    (1978)
  • JYN Lau et al.

    Significance of serum hepatitis C virus RNA levels in chronic hepatitis C

    Lancet

    (1993)
  • A Maynard

    Design of future cost benefit studies

    Am Heart J

    (1990)
  • GM Dusheiko

    Hepatitis C virus

  • JH Hoofnagle et al.

    Chronic viral hepatitis

  • MJ Alter et al.

    The natural history of community-acquired hepatitis C in the United States

    N Engl J Med

    (1992)
  • AS Lok et al.

    A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children

    Hepatology

    (1988)
  • YF Liaw et al.

    Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis

    Liver

    (1988)
  • C-M Chu et al.

    Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers

    Clin Infect Dis

    (1993)
  • C-M Chu et al.

    Intrahepatic expression of HBcAg in chronic HBV hepatitis: lessons from molecular biology

    Hepatology

    (1990)
  • AJ Weiner et al.

    Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections

  • P Simmonds et al.

    Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity

    J Gen Virol

    (1993)
  • S Guilhot et al.

    Hepatitis B virus (HBV)-specific cytotoxic Tcell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines

    J Virol

    (1992)
  • I-S Sheen et al.

    Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection

    J Infect Dis

    (1992)
  • Y-F Liaw et al.

    Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection

    J Med Virol

    (1992)
  • M Rizzetto et al.

    Hepatitis delta virus disease

    Prog Liver Dis

    (1986)
  • A Smedile et al.

    Presence and significance of hepatitis B virus replication in chronic type D hepatitis

    Prog Clin Biol Res

    (1991)
  • C-C Hsieh et al.

    Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study

    Am J Epidemiol

    (1992)
  • S Takase et al.

    The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease

    Hepatology

    (1993)
  • R Beasley

    Hepatitis B virus

  • WL Heywood et al.

    Serological markers of hepatitis B virus and alphafetoprotein levels preceding primary hepatocellular carcinoma in Alaskan Eskimos

    Lancet

    (1982)
  • M Sakamoto et al.

    Increasing incidence of hepatocellularcarcinoma possibly associated with non-A, non-B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgically resected cases

    Cancer Res

    (1988)
  • A Hadengue et al.

    Relative risk of hepatocellular carcinoma in HBsAg positive vs alcoholic cirrhosis

  • BJ McMahon et al.

    Hepatitis B-related sequelae

  • DA Shafritz et al.

    Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas

    Hepatology

    (1981)
  • T Yoneyama et al.

    Detection of hepatitis C virus cDNA sequence by the polymerase chain reaction in hepatocellular carcinoma tissues

    Jpn J Med Sci Biol

    (1990)
  • Cited by (145)

    • Drugs induced pulmonary arterial hypertension

      2013, Presse Medicale
      Citation Excerpt :

      In conclusion, large inhibition spectrum and lack of specificity of TKIs may be responsible for unexpected toxicities, even at the pulmonary vascular level. The interferons (IFNs) comprise an evolutionary conserved family of secreted proteins that participate as extracellular messengers in a wide variety of responses, including antiviral, antiproliferative and immunomodulatory and developmental activities that act to maintain homeostasis and in-host defence [42,43]. IFNs are classified as helical cytokines and are categorized as type I or type II, according to their physical and functional characteristics.

    • Economics of chronic hepatitis B and hepatitis C

      2007, Journal of Hepatology
      Citation Excerpt :

      Thus, considering only drug costs does not recognize the clinical benefit of treatment, so while a stricter stopping rule reduces drug costs, it does not incorporate the missed opportunity to eradicate hepatitis C infection. Table 4[38,39,48–53] summarizes published cost-effectiveness analyses in incremental cost per life-year gained and cost-utility analyses in incremental cost per QALY gained. Organized by comparator, the table starts first with the earliest effective therapies compared with placebo.

    • Drug induced pulmonary arterial hypertension

      2018, Interni Medicina pro Praxi
    • A mini-review of anti-hepatitis B virus activity of medicinal plants

      2017, Biotechnology and Biotechnological Equipment
    View all citing articles on Scopus

    The following investigators formed the advisory board: J.-P. Benhamou (France), V. Feinman (Canada), C. Niederau (Germany), M. Rizzetto (Italy), J. Rodés (Spain), J. Garcia de Ancos (United Kingdom), and S. Schalm (The Netherlands).

    View full text